ERBB2 and breast carcinoma: [89Zr]Zr-trastuzumab PET has shown to effectively distinguish between HER2-positive and HER2-negative lesions (9), detect HER2-positive metastases in patients with HER2-negative breast cancer, and exhibit increased uptake with higher immunohistochemistry scores (10–12).